Open AccessImmunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women
Author(s) -
Jessica A. Kahn,
Jiahong Xu,
Bill G. Kapogiannis,
Bret J. Rudy,
René Gonin,
Nancy Liu,
Craig M. Wilson,
Carol Worrell,
Kathleen Squires
Publication year - 2013
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cit319
Subject(s) - medicine , seroconversion , adverse effect , immunogenicity , hpv vaccines , cervical cancer , immunology , hpv infection , human immunodeficiency virus (hiv) , immune system , cancer
The objective of this study was to determine whether the 3-dose quadrivalent human papillomavirus (HPV) vaccine series (HPV-6, -11, -16, -18) is immunogenic and safe in young women infected with human immunodeficiency virus (HIV).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom